<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049060</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2011-001</org_study_id>
    <nct_id>NCT02049060</nct_id>
  </id_info>
  <brief_title>Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin</brief_title>
  <official_title>Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armando Santoro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, mono-centric, phase I-Ib trial of Tivantinib in&#xD;
      combination with Pemetrexed and Carboplatin as first-line therapy in patients with advanced&#xD;
      or metastatic cancer suitable for a Carboplatin and Pemetrexed regimen as part of their&#xD;
      specific therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, mono-centric, phase I-Ib trial of Tivantinib in&#xD;
      combination with Pemetrexed and Carboplatin as first-line therapy in patients with advanced&#xD;
      or metastatic cancer suitable for a Carboplatin and Pemetrexed regimen as part of their&#xD;
      specific therapy.This trial will be conducted to determine the maximum tolerated dose (MTD),&#xD;
      safety/tolerability, pharmacokinetics and preliminary anti-tumor activity of escalating doses&#xD;
      of Tivantinib in combination with standard fixed doses of Carboplatin and Pemetrexed.&#xD;
&#xD;
      The dose-escalation stage will be followed by an expansion stage at the MTD to better define&#xD;
      toxicity and clinical activity. MTD is defined as the highest dose level at which &lt; 33% of 6&#xD;
      patients experience a DLT.&#xD;
&#xD;
      Eligible patients will be enrolled and treated according to the following 3 + 3 design&#xD;
      starting from cohort 0:&#xD;
&#xD;
        -  1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks +&#xD;
           Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks 0 level: Tivantinib 240 mg p.o. BID +&#xD;
           Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3&#xD;
           weeks&#xD;
&#xD;
             -  1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks +&#xD;
                Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks&#xD;
&#xD;
      If the frequency of DLTs encountered at dose-level +1 will not fulfil the MTD definition,&#xD;
      then Tivantinib 360 mg bid in combination with Carboplatin AUC 5 and Pemetrexed 500 mg/mq&#xD;
      will be accepted as the recommended dose for phase IItrials.&#xD;
&#xD;
      Treatment will be continued on the basis of tumor assessment. Patients with stable disease,&#xD;
      complete or partial response will continue treatment until progressive disease, unacceptable&#xD;
      toxicity, patient or physician decision. For chemotherapy agents, however, a maximum of 6&#xD;
      cycles will be administered. Tivantinib will be continued until progressive disease,&#xD;
      unacceptable toxicity, patient or physician decision.&#xD;
&#xD;
      Toxicity will be graded according to the National Cancer Institute Common Toxicity Criteria&#xD;
      (NCI-CTC) version 3.&#xD;
&#xD;
      Following the dose-escalation phase of the study, additional patients (in order to reach a&#xD;
      total of 13 patients with MPM and 18 patients with NSCLC treated at MTD/recommended dose for&#xD;
      phase Ib trials) will be accrued to the expansion stage of this trial, to assess the&#xD;
      preliminary anti-tumor activity of Tivantinib in combination with Carboplatin (AUC 5) and&#xD;
      Pemetrexed (500 mg/mq) primarily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the dose limiting toxicities (DLTs) of Tivantinib</measure>
    <time_frame>18 months</time_frame>
    <description>1.To determine the dose limiting toxicities (DLTs) of Tivantinib given orally twice daily on a continuous schedule in combination with Carboplatin and Pemetrexed administered intra-venous every 3 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetics profile of Tivantinib in combination with Carboplatin and Pemetrexed</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the pharmacokinetics profile of Tivantinib in combination with Carboplatin (AUC 5) and Pemetrexed (500 mg/mq).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of Tivantinib with PFS</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the preliminary anti-tumor activity of Tivantinib in combination with Carboplatin (AUC 5) and Pemetrexed (500 mg/mq), in terms of 3-months progression-free survival rate for malignant pleural mesothelioma patients and 5-months progression-free survival rate for NSCLC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of Tivantinib with RECIST</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the preliminary anti-tumor activity of Tivantinib in combination with Carboplatin (AUC 5) and Pemetrexed (500 mg/mq), in terms of objective response rate according to &quot;response criteria evaluation criteria in solid tumors&quot; (Modified RECIST criteria for Malignant Pleural Mesothelioma), and duration of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate dynamic changes in blood levels</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate dynamic changes in blood levels of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met, in patients treated with Tivantinib in combination with Carboplatin (AUC 5) and Pemetrexed (500 mg/mq)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the expression of biomarkers</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the expression of phospho-c-Met, total c-Met, and downstream markers of c-Met signaling pathway in patients' tumor tissue samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To dermine the MTD of combination</measure>
    <time_frame>18 month</time_frame>
    <description>To determine the MTD of the combination, defined as the highest dosage cohort at which no more than one of six patients experiences a DLT during the first treatment cycle, considering the level +1 as the maximum level to explore. This will be the recommended dose for a subsequent phase II study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of tivantinib</measure>
    <time_frame>18 month</time_frame>
    <description>To assess the preliminary anti-tumor activity of Tivantinib in combination with Carboplatin (AUC 5) and Pemetrexed (500 mg/mq), in terms of 3-months progression-free survival rate for malignant pleural mesothelioma patients and 5-months progression-free survival rate for NSCLC patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <condition>Nonsquamous Nonsmall Cell Neoplasm of Lung</condition>
  <arm_group>
    <arm_group_label>Tivantinib+carboplatino+pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks&#xD;
•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks&#xD;
•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivantinib</intervention_name>
    <description>•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks&#xD;
•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks&#xD;
•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks</description>
    <arm_group_label>Tivantinib+carboplatino+pemetrexed</arm_group_label>
    <other_name>ARQ 197</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be diagnosed with MPM or non squamous NSCLC.&#xD;
&#xD;
          2. Inoperable disease according to local surgeon, not previously treated with&#xD;
             chemotherapy; patients relapsed/progressed after previous surgery will be also&#xD;
             evaluable for inclusion.&#xD;
&#xD;
          3. Age &gt; 18.&#xD;
&#xD;
          4. ECOG Performance Status 0-1 and life expectancy of at least 12 weeks.&#xD;
&#xD;
          5. Measurable and/or evaluable lesions according to modified RECIST criteria [51].&#xD;
&#xD;
          6. Written informed consent.&#xD;
&#xD;
          7. Patients must be accessible for treatment and follow up. Patients registered on this&#xD;
             trial must be treated and followed at the participating center.&#xD;
&#xD;
          8. Patients must use effective contraception during the study lasting at least one month&#xD;
             after the end of treatment for both sexes.&#xD;
&#xD;
          9. Laboratory requirements:&#xD;
&#xD;
               -  Neutrophils &gt;1.5 x 109/L and Platelets &gt;100 x 109/L&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 time the upper-normal limits (UNL) of the Institutional&#xD;
                  normal values, AST (SGOT) and ALT (SGPT) &lt; 2.5 x UNL, or &lt;5 x UNL in case of&#xD;
                  liver metastases, alkaline phosphatase &lt;2.5 x UNL, &lt; 5 x UNL in case of liver&#xD;
                  metastases, &lt;10 x UNL in case of bone metastases.&#xD;
&#xD;
               -  Creatinine clearance &gt;50 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior chemotherapy (including intracavitary administration).&#xD;
&#xD;
          2. Symptomatic and/or unstable pre-existing brain metastases.To be enrolled in the study&#xD;
             , subjects must have confirmation of stable disease by MRI or computer tomography (CT)&#xD;
             scan within 4 weeks from day 1 of cycle 1 of treatment and have CNS metastases well&#xD;
             controlled by steroids, anti - epileptics or other symptom-relieving medications&#xD;
&#xD;
          3. Serious non-healing wound or ulcer.&#xD;
&#xD;
          4. Evidence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          5. Uncontrolled hypertension.&#xD;
&#xD;
          6. Clinically significant (i.e. active) cardiovascular disease, for example&#xD;
             cerebrovascular accidents (&lt;6 months), myocardial infarction (&lt; 6 months), unstable&#xD;
             angina, New York Heart Association (NYHA) grade II or greater congestive heart&#xD;
             failure, serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
          7. Current treatment with anticoagulants for therapeutic purposes.&#xD;
&#xD;
          8. Treatment with any investigational drug within 30 days prior to enrolment.&#xD;
&#xD;
          9. Other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of basal cell carcinoma or cervical cancer in situ&#xD;
&#xD;
         10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study treatment start, or anticipation of the need for major surgical&#xD;
             procedure during the course of the study.&#xD;
&#xD;
         11. Pregnant or lactating women. Women of childbearing potential with either a positive or&#xD;
             no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at&#xD;
             least 12 months to be considered of non-childbearing potential. Sexually active males&#xD;
             and females (of childbearing potential) unwilling to practice contraception during the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Armando Santoro, MD</investigator_full_name>
    <investigator_title>Principal Investigators</investigator_title>
  </responsible_party>
  <keyword>MPM</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

